Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2

  • 78 Accesses

  • 18 Citations

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Berendt MJ, North RJ (1980) T cell-mediated suppression of antitumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151: 69

  2. 2.

    Borberg H, Oettgen HF, Choudry K, Beattie EJ (1972) Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors. Int J Cancer 10: 539

  3. 3.

    Chang AE, Hyatt CL, Rosenberg SA (1984) Systemic administration of recombinant IL-2 in mice. J Biol Resp Modif 3: 561

  4. 4.

    Cheever MA, Greenberg PD, Fefer A (1984) Potential for specific cancer therapy with immune T lymphocytes. J Biol Resp Modif 3: 113

  5. 5.

    Cheever MA, Kempf RA, Fefer A (1977) Tumor neutralization, immunotherapy, and chemoimmunotherapy of a friend leukemia with cells secondarily sensitized in vitro. J Immunol 119: 714

  6. 6.

    Delorme EJ (1984) Treatment of primary fibrosarcoma in the rat with immune lymphocytes. Lancet 11: 117

  7. 7.

    Eberlein TJ, Rosenstein M, Rosenberg SA (1982) Adoptive chemoimmunotherapy of a syngeneic murine lymphoma using long-term lymphoid cell lines expanded in T cell growth factor. Cancer Immunol Immunother 13: 5

  8. 8.

    Eberlein TJ, Rosenstein M, Rosenberg SA (1982) Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in IL-2. J Exp Med 156: 385

  9. 9.

    Ettinghausen SE, Lipford EH III, Mulé JJ, Rosenberg SA (1985) Recombinant interleukin-2 stimulates in vivo proliferation of adoptively transferred lymphokine activated killer (LAK) cells. J Immunol 135: 3623

  10. 10.

    Ettinghausen SE, Lipford EH III, Mulé JJ, Rosenberg SA (1985) Systemic administration of recombinant interleukin-2 stimulates in vivo lymphoid cell proliferation in tissues. J Immunol 135: 1488

  11. 11.

    Fernandez-Cruz E, Halliburton B, Feldman JD (1979) In vivo elimination by specific effector cells of an established syngeneic rat Moloney virus-induced sarcoma. J Immunol 123: 1772

  12. 12.

    Fefer A, Cheever MA, Greenberg PD (1982) Lymphocyte transfer as potential cancer immunotherapy. In: Mihich E (ed) Immunological approaches to cancer therapies. John Wiley and Sons, New York, p 333

  13. 13.

    Fefer A, Einstein AB Jr, Cheever MA, Berenson JR (1976) Models for syngeneic adoptive chemoimmunotherapy of murine leukemias. Ann NY Acad Sci 277: 492

  14. 14.

    Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) The lymphokine activated killer cell phenomenon: lysis of NK resistant fresh solid tumor cells by IL-2 activated autologus human peripheral blood lymphocytes. J Exp Med 155: 1823

  15. 15.

    Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djen JY, Rosenberg SA (1983) Lymphokine-activated killer cell phenomenon: II. The precursor phenotype is serologically distinct from peripheral T lymphocytes, memory CTL, and NK cells. J Exp Med 157: 884

  16. 16.

    Grimm EA, Robb RJ, Roth JA, Neckers LM, Lachman LB, Wilson DJ, Rosenberg SA (1983) Lymphokine-activated killer cell (LAK) phenomenon: III. Evidence that IL-2 alone is sufficient for direct activation of PBL into LAK. J Exp Med 158: 1356

  17. 17.

    Grimm EA, Rosenberg SA (1984) The human lymphokine-activated killer cell phenomenon. In: Pick E (ed) Lymphokines, Vol 9. Academic Press, Orlando, p 279

  18. 18.

    Hellstrom KE, Hellstrom I (1981) Cell-mediated suppression of tumor immunity has a nonspecific component. I. Evidence from transplantation tests. Int J Cancer 27: 481

  19. 19.

    Hellstrom KE, Hellstrom I, Kant JA, Tanerius J (1978) Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population. J Exp Med 148: 799

  20. 20.

    Kedar E, Weiss DW (1983) The in vitro generation of effector lymphocytes and their employment in tumor immunotherapy. Adv Cancer Res 38: 171

  21. 21.

    Lafreniere R, Rosenberg SA (1986) A novel approach to the generation and identification of hepatic metastases in the murine system. JNCI in press

  22. 22.

    Lafreniere R, Rosenberg SA (1985) Adoptive immunotherapy to murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin-2 (RIL-2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol 135: 4273

  23. 23.

    Lafreniere R, Rosenberg SA (1985) Successful immunotherapy of experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res 45: 3735

  24. 24.

    Lotze MT, Grimm E, Mazumder A, Strausser JL, Rosenberg SA (1981) In vitro growth of cytotoxic human lymphocytes. IV. Lysis of fresh and cultured autologous tumor by lymphocytes cultured in T cell growth factor (TCGF). Cancer Res 41: 4420

  25. 25.

    Lotze MT, Matory YL, Ettinghausen SE, Rayner A, Sharrow SO, Seipp CAY, Custer M, Rosenberg SA (1985) In vivo administration of purified human interleukin-2 II. Half-life, immunologic effects and expansion of peripheral lymphoid cells in vivo with recombinant interleukin-2. J Immunol 135: 2865

  26. 26.

    Matory YL, Chang AE, Lipford EH III, Braziel R, Hyatt CL, McDonald HD, Rosenberg SA (1985) Toxicity of recombinant human interleukin-2 in rats following intravenous infusion. J Biol Resp Modif 4: 377

  27. 27.

    Mazumder A, Rosenberg SA (1983) Lysis of fresh human solid tumors by activated autologous lymphocytes: potential applications to tumor immunotherapy. In: Chabner B (ed) Rational basis for chemotherapy. Alan R. Liss, New York, p 359

  28. 28.

    Mazumder A, Rosenberg SA (1984) Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. J Exp Med 159: 495

  29. 29.

    Morgan DA, Ruscetti FW, Gallo RC (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007

  30. 30.

    Mulé JJ, Ettinghausen SE, Spiess PJ, Shu S, Rosenberg SA (1985) Anti-tumor efficacy of lymphokine-activated killer cells and recombinant IL-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. Cancer Res 46: 676

  31. 31.

    Mule JJ, Rosenberg SA (1986) Successful adoptive immunotherapy of established metastases with lymphokine activated killer cells and recombinant interleukin-2. In: Herberman RB (ed) Immune responses to metastases. CRC Press Boca Raton, (in press)

  32. 32.

    Mulé JJ, Shu S, Rosenberg SA (1985) The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo. J Immunol 135: 646

  33. 33.

    Mulé JJ, Shu S, Schwarz SL, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487

  34. 34.

    North RJ, Dye ES, Mills CD (1981) T cell-mediated negative regulation of concomitant anti-tumor immunity as an obstacle to adoptive immunotherapy of established tumors. In: Fefer A, Goldstein AL (eds) The potential role of T cell populations in cancer therapy, Raven Press, New York, p 65

  35. 35.

    Rayner AA, Grimm EA, Lotze MT, Chu EW, Rosenberg SA (1985) Lymphokine-activated killer (LAK) cells: analysis of factors relevant to the immunotherapy of human cancer. Cancer 55: 1327

  36. 36.

    Rosenberg SA (1984) Adoptive immunotherapy of cancer: accomplishments and prospects. Cancer Treat Rep 68: 233

  37. 37.

    Rosenberg SA (1985) Lymphokine-activated killer cells: a new approach to the immunotherapy of cancer. JNCI 75: 595

  38. 38.

    Rosenberg SA, Terry W (1977) Passive immunotherapy of cancer in animals and man. Adv Cancer Res 25: 323

  39. 39.

    Rosenberg SA, Mulé JJ (1985) Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2. Surgery 98: 437

  40. 40.

    Rosenberg SA, Eberlein TJ, Grimm EA, Lotze MT, Mazumder A, Rosenstein M (1982) Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer. Surgery 92: 328

  41. 41.

    Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF (1984) Biological activity of recombinant human interkeukin-2 produced in E. coli. Science 223: 1412

  42. 42.

    Rosenberg SA, Rosenstein M, Grimm EA, Lotze MT, Mazumder A (1984) The use of lymphoid cells expanded in IL-2 for the adoptive immunotherapy of murine and human tumors. In: Goldstein AL (ed) Thymic hormones and lymphokines. Plenum Publ Corp, New York, p 191

  43. 43.

    Rosenberg SA, Shu S, Mulé JJ (1984) Approaches to the adoptive immunotherapy of cancer. In: Aoki T, Urushizaki I, Tsubara E (eds) Manipulation of host defense mechanisms. Excerpta Medica, Amsterdam, p 70

  44. 44.

    Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA (1984) Lymphokine activated killer cells: lysis of fresh syngeneic NK-resistant murine tumor cells by lymphocytes cultured in interleukin-2. Cancer Res 44: 1946

  45. 45.

    Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161: 1169

  46. 46.

    Shu S, Fonseca LS, Kato H, Zbar B (1983) Mechanisms of immunological eradication of syngeneic guinea pig tumor: participation of a component(s) of recipient origin in the expression of systemic adoptive immunity. Cancer Res 43: 2637

  47. 47.

    Smith H, Harmel RP, Hanna MG, Zwilling BS, Zbar B, Rapp HJ (1977) Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells. JNCI 58: 1315

  48. 48.

    Taniguchi T, Matsui H, Fajita T, Takaoko C, Kashima N, Yoshimoto R, Hamuro J (1983) Structure and expression of a cloned cDNA for human interleukin-2. Nature 302: 305

  49. 49.

    Wexler H (1966) Accurate identification of experimental pulmonary metastases. JNCI 36: 641

  50. 50.

    Yron I, Wood TA, Spiess PJ, Rosenberg SA (1980) In vitro growth of murine T-cells: V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 125: 238

Download references

Author information

Correspondence to Stephen E. Ettinghausen.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ettinghausen, S.E., Rosenberg, S.A. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. Springer Semin Immunopathol 9, 51–71 (1986). https://doi.org/10.1007/BF00201905

Download citation

Keywords

  • Internal Medicine
  • Killer Cell
  • Activate Killer
  • Activate Killer Cell
  • Adoptive Immunotherapy